Low‐intervention clinical trials in Spain: Do they progress?
British Journal of Clinical Pharmacology · 2025
DOI: 10.1002/bcp.70409 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Claudia Erika Delgado-Espinoza und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Therapeutics, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain. Hauptthemen laut MEDLINE: Clinical Trials as Topic, Pragmatic Clinical Trials as Topic. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Aims
Low‐Intervention Clinical Trials (LICTs) are generally pragmatic trials that investigate medicinal products already authorized for use. In 2014, simplified regulatory frameworks were introduced for LICTs with the aim of reducing regulatory burden and operational complexity, to foster non‐commercial clinical trials (NCCTs); the mandatory implementation of CTIS in 2023 may have impacted LICTs feasibility. Our aim was to describe the main characteristics of LICTs approved in Spain over a ten‐year period.
Methods
Cross‐sectional descriptive analysis of LICTs registered between 2014 and 2023, in the Spanish Clinical Studies Registry (REec) database, mandatory to all authorized trials.
Results
Between January 2014 and December 2023, 8497 clinical trials were registered in REec, of which only 3.8% (N = 322) were classified as LICTs. No drop in the overall proportion of LICTs was seen in 2023. Most LICTs were sponsored by non‐commercial entities and funded primarily through sponsors' own resources. LICTs were frequently monocentric phase IV studies evaluating commercialized medicinal products. The principal objectives of the trials included efficacy and/or safety, while pharmacoeconomics, pharmacogenetics, pharmacogenomics and bioequivalence were comparatively infrequent as main objectives. Most trial designs were randomized, but blinded trials were less frequent, and only a minority were placebo‐controlled.
Conclusions
Despite their critical role in establishing effectiveness and safety of authorized medicinal products in pragmatic clinical settings, LICTs still constitute a relatively small proportion of all clinical trials approved in Spain, and their designs have area for improvement in terms of robustness. There was no apparent effect of CTIS implementation on LICTs activity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology and Therapeutics, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
- Department of Clinical Pharmacology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
- Pharmacological Research in Humans, Institut de Recerca Sant Pau (IR SANTPAU), Barcelona, Spain.
ORCID-Profile: Claudia Erika Delgado-Espinoza, Mayro J Cortés Pestana, Kristopher Amaro, Rosa M Antonijoan, Caridad Pontes
Zitieren
APA
Delgado-Espinoza, C. E., Cortés Pestana, M. J., Amaro, K., Antonijoan, R. M., & Pontes, C. (2025). Low‐intervention clinical trials in Spain: Do they progress?. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70409
Vancouver
Delgado-Espinoza CE, Cortés Pestana MJ, Amaro K, Antonijoan RM, Pontes C. Low‐intervention clinical trials in Spain: Do they progress?. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70409
BibTeX
@article{DelgadoEspinoza2025,
author = {Delgado-Espinoza, Claudia Erika and Cortés Pestana, Mayro J and Amaro, Kristopher and Antonijoan, Rosa M and Pontes, Caridad},
title = {Low‐intervention clinical trials in Spain: Do they progress?},
journal = {British Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1002/bcp.70409}
}
EUVIMED